Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC,Extensive Stage × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 79 Breast Neoplasms 55 Prostatic Neoplasms 29 Neoplasms 23 Triple Negative Breast Neoplasms 22 Fallopian Tube Neoplasms 21 Endometrial Neoplasms 17 Pancreatic Neoplasms 16 Neoplasm Metastasis 15 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 10 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Sarcoma 8 Carcinoma, Non-Small-Cell Lung 8 Recurrence 7 Glioma 7 Lung Neoplasms 6 Fanconi Anemia, Complementation Group D1 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Glioblastoma 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Advanced Solid Tumors 4 Advanced Breast Cancer 4

Interventions

Etoposide 2 pembrolizumab 1 olaparib 1 niraparib 1 atezolizumab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡